Bio2 Technologies, Inc.
Woburn, MA 02115, US
Medical Devices & Equipment
Bio2 is commercializing Vitrium, a novel biomaterial for use in orthopedic surgery. Vitrium fully resorbs while stimulating the remodeling of new, heathy bone. The first line of Vitrium products was recently cleared by the FDA.
Vitrium has broad application across a $50B global market. The application opportunities have pre-existing reimbursement and do not require modification of surgical techniques. The cost of manufacturing Vitrium products is at or below that of competitive technologies.
Future applications of Vitrium include cartilage regeneration, limb salvage and treatment of osteoporotic bone.
Bio2 currently has two active product development programs:
– Reconstructive surgery of the foot and ankle. Bio2 is currently releasing implants fours in the correction of flatfoot deformity and hammertoe repair.
– Spinal fusion. The final pre-clinical study for a cervical fusion device is in process with pitfall data expected in October 2016.
Our proprietary process is protective by a portfolio of issued patents in the US, Japan, China and Israel with patents pending in the EU.
Our management team has deep domain experience and a successful entrepreneurial track record in the orthopedics space. Bio2’s directors and advisors include veteran industry figures and recognized clinical and scientific thought leaders.
Our capital efficient business model seeks to drive IRR through engaging strategic partners across multiple sub-specialty market verticals. Investor capital is employed exclusively for product development, securing global regulatory approvals and manufacturing infrastructure.
Products / Services
Orthopedic Biomaterials/Implantable devices
Resorbable implants for use in reconstructive surgery, joint fusion and regenerative medicine.
Paul K. Nichols Jr.